Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > What to expect

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jun 14, 2022 9:58am

223 Views

Post# 34754728

RE:What to expect

....I'm gonna to add a bit at these prices. 2022, IMO & that of many others, is the year things happen. Bracelet full enrollment, Bracelet data, possibly two phase 3's running concurrently & Car-T. This has to be the most consequential yr of Oncy's existence...get things done or people jump ship.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?